Johnson & Johnson (NYSE:JNJ) Short Interest Update

Johnson & Johnson (NYSE:JNJ) was the recipient of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 25,086,679 shares, a growth of 20.8% from the February 12th total of 20,767,056 shares. Approximately 1.0% of the company’s shares are short sold. Based on an average daily volume of 10,013,422 shares, the days-to-cover ratio is currently 2.5 days. Based on an average daily volume of 10,013,422 shares, the days-to-cover ratio is currently 2.5 days. Approximately 1.0% of the company’s shares are short sold.

Insider Activity at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of JNJ. AustralianSuper Pty Ltd raised its stake in Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock worth $16,536,000 after acquiring an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. boosted its stake in Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares in the last quarter. Guinness Asset Management LTD grew its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock worth $251,216,000 after purchasing an additional 5,994 shares during the last quarter. Treasurer of the State of North Carolina increased its position in shares of Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares in the last quarter. Finally, National Pension Service lifted its holdings in shares of Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after purchasing an additional 151,707 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $5.01 during trading on Tuesday, reaching $238.18. 7,279,967 shares of the company’s stock traded hands, compared to its average volume of 8,567,776. The firm has a market cap of $573.68 billion, a PE ratio of 21.55, a P/E/G ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $233.35 and a 200-day simple moving average of $207.56.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on JNJ shares. Loop Capital set a $220.00 target price on shares of Johnson & Johnson in a research report on Tuesday, January 27th. Stifel Nicolaus raised their price target on Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Daiwa Securities Group raised their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Finally, Freedom Capital downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $236.57.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: HSBC raised its price target on JNJ to $280 and upgraded to a “buy,” calling for meaningful upside versus current levels — a fresh, high‑profile endorsement that supports longer‑term bullishness. Article Title
• Positive Sentiment: Independent analyst pieces highlight a $280 target and argue JNJ’s recent outperformance (strong YTD and 1‑yr gains) is backed by pipeline and portfolio strength — reinforcing the narrative of further upside for investors who can wait. Why One Analyst Thinks Johnson & Johnson Reaches $280
• Positive Sentiment: JNJ reported a phase I win for its bladder cancer therapy (Erda‑iDRS) with strong responses and manageable safety — clinical progress that could support future revenue if later‑stage trials succeed. JNJ’s Bladder Cancer Therapy Meets Key Goal
• Positive Sentiment: Regulatory progress for TECVAYLI (teclistamab) — J&J submitted a Type II variation to the EMA seeking approval in relapsed/refractory multiple myeloma — an important potential mid‑term revenue catalyst if approved. TECVAYLI Opportunity
• Neutral Sentiment: Johnson & Johnson launched pulsed field ablation tech in Peru — incremental product expansion in med‑tech markets, supportive but unlikely to meaningfully shift near‑term revenue. PFA Peru Launch
• Neutral Sentiment: Industry news (e.g., Monte Rosa supply agreement) and market commentary reassessing JNJ’s valuation after large multi‑year gains — useful context for positioning but not company‑specific catalysts. Monte Rosa Agreement
• Negative Sentiment: Shares slid today even as the broader market rose — coverage notes the drop reflects short‑term profit‑taking and rotation after a strong run, as well as lighter-than-average volume. That intraday weakness outweighed the new buy rating and clinical headlines. JNJ Stock Slides

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.